Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) accounts for 85%–90% of all cases of lung cancer that is the most deadly type of cancer. Despite advances in chemotherapy and radiotherapy, severe side effects and frequent drug resistance limit the success of the treatments, and the identification of new therapeut...
Main Authors: | Silvia Nuzzo, Silvia Catuogno, Maria Capuozzo, Alfonso Fiorelli, Piotr Swiderski, Serena Boccella, Filomena de Nigris, Carla Lucia Esposito |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253119301635 |
Similar Items
-
STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma
by: Carla Lucia Esposito, et al.
Published: (2018-03-01) -
Updates on HIPK2: a resourceful oncosuppressor for clearing cancer
by: D’Orazi Gabriella, et al.
Published: (2012-08-01) -
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery
by: Silvia Catuogno, et al.
Published: (2019-12-01) -
Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma
by: M. Mazzoni, et al.
Published: (2022-12-01) -
Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer
by: Marcello Rubino, et al.
Published: (2017-07-01)